The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein; Caffeine inhibits the reaction [3,4-dihydroxyphenylglycol results in increased activity of PLCB1 protein]; Caffeine inhibits the reaction [[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein]; Theophylline inhibits the reaction [3,4-dihydroxyphenylglycol results in increased activity of PLCB1 protein]; Theophylline inhibits the reaction [[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein]
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of AKT1 mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of AKT1 protein
astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of and results in decreased activity of ATP2A2 protein]; astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of ATP2A2 mRNA]
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CASP3 protein modified form] astragaloside A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein]
astragaloside IV decreases expression Dusp5 mRNA and protein in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate increases expression of DUSP5 mRNA and protein in Vascular smooth muscle cells]
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of EGFR mRNA
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein]
astragaloside IV increases expression H19 RNA in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases expression of H19 RNA in Vascular smooth muscle cells]
astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of HDAC9 protein]
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein astragaloside A results in increased expression of HMOX1 mRNA; astragaloside A results in increased expression of HMOX1 protein
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL1B protein; astragaloside A inhibits the reaction [Cisplatin results in increased expression of IL1B protein]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein]
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL6 protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein] astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]
astragaloside IV decreases expression of Khdrbs1 protein in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate astragaloside IV increases expression of KHDRBS1 protein in Vascular smooth muscle cells]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein]
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of MMP9 protein
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of MTOR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MTOR mRNA astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases phoshorylation of MTOR protein in Vascular smooth muscle cells] astragaloside IV increases phosphorylation Mtor protein in thoracic aorta
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5AC mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of MUC5AC protein
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5B mRNA
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein astragaloside A affects the localization of NFE2L2 protein
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein]
astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein]
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein]
astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein]
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of TIMP1 protein
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of TNF protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein] astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]
bellidifolin inhibits the reaction [Hydrogen Peroxide results in increased expression of AKT1 mRNA]; bellidifolin inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased phosphorylation of AKT1 protein]
bellidifolin inhibits the reaction [Isoproterenol results in increased expression of BRD4 mRNA]; bellidifolin inhibits the reaction [Isoproterenol results in increased expression of BRD4 protein]
bellidifolin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of GSDMD protein alternative form]; bellidifolin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GSDMD protein]
bellidifolin inhibits the reaction [Hydrogen Peroxide results in increased expression of GSK3B mRNA]; bellidifolin inhibits the reaction [Hydrogen Peroxide results in increased expression of GSK3B protein]
bellidifolin inhibits the reaction [Isoproterenol results in increased expression of NOX4 mRNA]; bellidifolin inhibits the reaction [Isoproterenol results in increased expression of NOX4 protein]
bellidifolin inhibits the reaction [TGFB1 protein results in increased expression of SOX9 protein] bellidifolin inhibits the reaction [Isoproterenol results in increased expression of SOX9 protein]
bellidifolin results in decreased expression of and results in decreased phosphorylation of STAT3 protein bellidifolin results in decreased expression of STAT3 mRNA
bellidifolin inhibits the reaction [TGFB1 protein results in increased expression of SMAD4 protein]; bellidifolin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] bellidifolin inhibits the reaction [TGFB1 protein results in increased expression of SOX9 protein]; bellidifolin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] bellidifolin inhibits the reaction [TGFB1 protein results in increased expression of and results in increased phosphorylation of SMAD2 protein]; bellidifolin inhibits the reaction [TGFB1 protein results in increased expression of and results in increased phosphorylation of TGFBR1 protein]; bellidifolin inhibits the reaction [TGFB1 protein results in increased expression of and results in increased phosphorylation of TGFBR2 protein]; bellidifolin inhibits the reaction [TGFB1 protein results in increased expression of SMAD4 protein]; bellidifolin inhibits the reaction [TGFB1 protein results in increased phosphorylation of and affects the localization of NR4A1 protein]; bellidifolin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]
ABCB1 protein results in increased transport of benzoylaconine [Cyclosporine results in decreased activity of ABCB1 protein] which results in decreased transport of benzoylaconine; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased transport of benzoylaconine
ABCB1 protein results in increased transport of benzoylmesaconine [Cyclosporine results in decreased activity of ABCB1 protein] which results in decreased transport of benzoylmesaconine; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased transport of benzoylmesaconine
[conduritol epoxide binds to and results in decreased activity of GBA1 protein] which results in increased expression of SNCA protein [conduritol epoxide binds to and results in decreased activity of GBA1 protein] which affects the localization of SNCA protein; [conduritol epoxide binds to and results in decreased activity of GBA1 protein] which results in increased expression of SNCA protein conduritol epoxide analog results in decreased activity of GBA1 protein
[conduritol epoxide binds to and results in decreased activity of GBA1 protein] which affects the localization of SNCA protein; [conduritol epoxide binds to and results in decreased activity of GBA1 protein] which results in increased expression of SNCA protein
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il6 protein in spleenocytes and peripheral blood] cycloastragenol inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased secretion of IL6 protein]
cycloastragenol inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of TERT protein]; cycloastragenol inhibits the reaction [Benzo(a)pyrene results in decreased expression of TERT protein]
Dipyridamole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Dipyridamole results in decreased activity of ABCB11 protein
Dipyridamole results in decreased activity of ABCC4 protein Dipyridamole inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]
[Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with Atorvastatin co-treated with Valsartan] results in decreased expression of APOE protein
Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 protein]
Dipyridamole inhibits the reaction [Adenosine results in increased activity of CASP3 protein]; Palmitic Acid promotes the reaction [Dipyridamole results in increased activity of CASP3 protein]
Dipyridamole results in increased activity of CASP7 protein Palmitic Acid promotes the reaction [Dipyridamole results in increased activity of CASP7 protein]
Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; tin protoporphyrin IX inhibits the reaction [Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]] Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]
Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA alternative form]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR protein]
Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]] Dipyridamole results in decreased expression of COL1A1 mRNA
Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]]
Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO mRNA]; Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO protein]
Dipyridamole results in increased phosphorylation of DUSP1 protein DUSP1 mRNA affects the reaction [Dipyridamole inhibits the reaction [cobaltous chloride results in increased expression of SPP1 protein]]; HMOX1 mRNA affects the reaction [Dipyridamole results in increased phosphorylation of DUSP1 protein] DUSP1 mRNA affects the reaction [Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]
Dipyridamole results in increased expression of HMOX1 protein HMOX1 mRNA affects the reaction [Dipyridamole results in increased phosphorylation of DUSP1 protein]
Dipyridamole promotes the reaction [8-bromocyclic GMP promotes the reaction [IL1B protein results in increased abundance of Nitrites]]; Dipyridamole promotes the reaction [Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]]; Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; KT 5720 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; KT 5823 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]
Dipyridamole inhibits the reaction [AICA ribonucleotide results in decreased activity of INSR promoter]; Dipyridamole inhibits the reaction [AICA ribonucleotide results in decreased expression of INSR mRNA]; Dipyridamole inhibits the reaction [AICA ribonucleotide results in decreased expression of INSR protein]
Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
Dipyridamole results in increased expression of NOS2 mRNA; Dipyridamole results in increased expression of NOS2 protein Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]
Dipyridamole inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP] Dipyridamole inhibits the reaction [PDE8A protein results in increased hydrolysis of Cyclic AMP]
Dipyridamole inhibits the reaction [PDE8B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]
Dipyridamole results in increased secretion of PLAT protein KT 5823 inhibits the reaction [Dipyridamole results in increased secretion of PLAT protein]
Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; DUSP1 mRNA affects the reaction [Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; triptolide inhibits the reaction [Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]] Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; tin protoporphyrin IX inhibits the reaction [Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]
Dipyridamole inhibits the reaction [SLC22A2 protein polymorphism results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Dipyridamole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
Dipyridamole inhibits the reaction [4-nitrobenzylthioinosine binds to SLC29A1 protein]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Dipyridamole promotes the reaction [4-nitrobenzylthioinosine inhibits the reaction [[SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine]] Dipyridamole inhibits the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]; Dipyridamole promotes the reaction [[SLC29A1 co-treated with Oxygen deficiency] affects the abundance of Adenosine] Dipyridamole results in decreased activity of SLC29A1 protein
Dipyridamole promotes the reaction [4-nitrobenzylthioinosine inhibits the reaction [[SLC29A1 protein co-treated with SLC29A2 protein] results in increased uptake of Uridine]] Dipyridamole inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine]
Dinitrochlorobenzene inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; Dipyridamole inhibits the reaction [cobaltous chloride results in increased expression of SPP1 protein]; Dipyridamole inhibits the reaction [Glucose results in increased expression of SPP1 mRNA]; Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]; DUSP1 mRNA affects the reaction [Dipyridamole inhibits the reaction [cobaltous chloride results in increased expression of SPP1 protein]]; KT 5823 inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; tin protoporphyrin IX inhibits the reaction [Dipyridamole inhibits the reaction [cobaltous chloride results in increased expression of SPP1 protein]]
Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]]
Dipyridamole inhibits the reaction [Glucose results in decreased expression of TXN1 protein]; KT 5823 inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in decreased expression of TXN1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in decreased expression of TXN1 protein]]
Dipyridamole results in increased secretion of VEGFA protein Adenosine promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein]; Heparitin Sulfate promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein]; Hyaluronic Acid promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein]; Lipopolysaccharides promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein]
madecassoside inhibits the reaction [Cisplatin results in increased expression of BAX mRNA] madecassoside inhibits the reaction [Cisplatin results in increased expression of BAX mRNA]; madecassoside inhibits the reaction [Cisplatin results in increased expression of BAX protein]
madecassoside inhibits the reaction [Cisplatin results in increased expression of LCN2 mRNA]; madecassoside inhibits the reaction [Cisplatin results in increased expression of LCN2 protein]
Masoprocol inhibits the reaction [ALOX12 protein results in increased chemical synthesis of 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid] Masoprocol results in decreased activity of ALOX12 protein
Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] Masoprocol results in decreased activity of ALOX15 protein [Masoprocol results in decreased activity of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid
ALOX5 protein affects the susceptibility to Masoprocol Masoprocol results in decreased activity of ALOX5 protein Masoprocol inhibits the reaction [[CCL5 protein co-treated with Calcimycin] results in increased expression of ALOX5 mRNA]; Masoprocol inhibits the reaction [[CCL5 protein co-treated with Calcimycin] results in increased expression of ALOX5 protein] [Masoprocol results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [Masoprocol results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; Masoprocol inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]
Masoprocol results in increased cleavage of CASP3 protein Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased cleavage of and results in increased activity of CASP3 protein]; Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased expression of CASP3 protein] acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Masoprocol results in increased activity of CASP3 protein]; Masoprocol inhibits the reaction [FASL protein results in increased activity of CASP3 protein] [Masoprocol co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein
[Masoprocol co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein Masoprocol inhibits the reaction [FASL protein results in increased activity of CASP8 protein] Masoprocol results in increased expression of CASP8 protein
Masoprocol inhibits the reaction [[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4]; Masoprocol inhibits the reaction [[CCL5 protein co-treated with Calcimycin] results in increased expression of ALOX5 mRNA]; Masoprocol inhibits the reaction [[CCL5 protein co-treated with Calcimycin] results in increased expression of ALOX5 protein]
Masoprocol results in decreased methylation of CDH1 promoter Masoprocol results in increased expression of CDH1 mRNA; Masoprocol results in increased expression of CDH1 protein
Masoprocol results in decreased methylation of CDKN2A promoter Masoprocol results in increased expression of CDKN2A mRNA; Masoprocol results in increased expression of CDKN2A protein
Masoprocol promotes the reaction [sodium arsenite results in increased expression of CRYAB mRNA]; Masoprocol promotes the reaction [sodium arsenite results in increased expression of CRYAB protein]
Masoprocol inhibits the reaction [FASL protein results in increased activity of CASP3 protein]; Masoprocol inhibits the reaction [FASL protein results in increased activity of CASP8 protein] Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased expression of FASLG protein]
Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of and results in increased secretion of MMP13 protein]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of CHUK protein modified form]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of MAPK8 protein modified form]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of MAPK9 protein modified form]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of NFKBIA protein modified form]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of RELA protein modified form]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased phosphorylation of MAPK1 protein]; Masoprocol inhibits the reaction [FN1 protein modified form results in increased phosphorylation of MAPK3 protein]
12-Hydroxy-5,8,10,14-eicosatetraenoic Acid inhibits the reaction [Masoprocol results in increased activity of HSD11B2 protein]; 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid inhibits the reaction [Masoprocol results in increased expression of HSD11B2 mRNA]; [Masoprocol co-treated with 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid] results in decreased expression of HSD11B2 protein; [Masoprocol co-treated with Leukotriene B4] results in decreased expression of HSD11B2 protein; Leukotriene B4 inhibits the reaction [Masoprocol results in increased activity of HSD11B2 protein]; Masoprocol inhibits the reaction [Progesterone results in decreased activity of HSD11B2 protein]; Masoprocol promotes the reaction [Mifepristone results in increased activity of HSD11B2 protein]
Masoprocol inhibits the reaction [IGF1 protein promotes the reaction [IGF1R protein results in increased phosphorylation of and results in increased activity of IGF1R protein]]; Masoprocol inhibits the reaction [IGF1 protein results in increased phosphorylation of ERBB2 protein]; Masoprocol inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]
Masoprocol inhibits the reaction [Dihydrotestosterone results in increased expression of IGF1R mRNA]; Masoprocol inhibits the reaction [Dihydrotestosterone results in increased expression of IGF1R protein]; Masoprocol inhibits the reaction [IGF1 protein promotes the reaction [IGF1R protein results in increased phosphorylation of and results in increased activity of IGF1R protein]]; Masoprocol inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein] Masoprocol results in decreased activity of IGF1R protein
Masoprocol inhibits the reaction [Eicosapentaenoic Acid inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Masoprocol inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Masoprocol inhibits the reaction [IL1B protein results in increased expression of MMP13 protein] Masoprocol results in decreased susceptibility to IL1B protein Masoprocol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
Masoprocol results in decreased expression of JUN mRNA Masoprocol inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of [FOS protein co-treated with JUN protein]]
Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]
Masoprocol inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; Masoprocol inhibits the reaction [LHB protein results in increased abundance of Pregnenolone]; Masoprocol inhibits the reaction [LHB protein results in increased abundance of Testosterone]
Masoprocol inhibits the reaction [FN1 protein modified form results in increased phosphorylation of MAPK1 protein] Masoprocol results in decreased phosphorylation of MAPK1 protein
Masoprocol results in decreased phosphorylation of MAPK3 protein Masoprocol inhibits the reaction [FN1 protein modified form results in increased phosphorylation of MAPK3 protein]
Masoprocol inhibits the reaction [FN1 protein modified form results in increased expression of and results in increased secretion of MMP13 protein]; Masoprocol inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Masoprocol inhibits the reaction [IL1B protein results in increased expression of MMP13 protein]; Masoprocol inhibits the reaction [TNF protein results in increased expression of MMP13 mRNA]; Masoprocol inhibits the reaction [TNF protein results in increased expression of MMP13 protein]
Masoprocol results in increased expression of MYC protein MYC affects the reaction [Masoprocol results in increased expression of BAX protein]; MYC affects the reaction [Masoprocol results in increased expression of MYC protein]; MYC affects the reaction [Masoprocol results in increased expression of TP53 protein]
Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased expression of NGF mRNA]; Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased expression of NGF protein]
Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased expression of NGFR mRNA]; Masoprocol inhibits the reaction [pentaacetyl geniposide results in increased expression of NGFR protein]
Masoprocol affects the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of PCNA protein]
Masoprocol inhibits the reaction [POR protein affects the reaction [Benzo(a)pyrene results in increased chemical synthesis of benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide-DNA]]
Masoprocol inhibits the reaction [Eicosapentaenoic Acid inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Masoprocol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Masoprocol inhibits the reaction [TNF protein results in increased expression of SOD2 mRNA]
Masoprocol inhibits the reaction [TNF protein results in increased expression of MMP13 mRNA]; Masoprocol inhibits the reaction [TNF protein results in increased expression of MMP13 protein]; Masoprocol inhibits the reaction [TNF protein results in increased expression of SOD2 mRNA] Masoprocol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] Masoprocol results in decreased susceptibility to TNF protein
[Masoprocol co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of BID protein; [Masoprocol co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP10 protein; [Masoprocol co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [Masoprocol co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein
Masoprocol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA mRNA]; Masoprocol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of VEGFA protein]